2006 Publications


  1. Llovet JM, Chen Y, Wurmbach W, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman S. A molecular signature to discriminate dysplastic nodules and early hepatocellular carcinoma in HCV-cirrhosis. Gastroenterology 2006; 131: 1758-1767.

  2. Mazzaferro V, Romito R,. Schiavo M, Mariani L, Camerini T,Capussotti L, Calise F, Pellicci R, Belli G, Tagger A,  Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.Hepatology. 2006;44:1543-54.


  1. Fattovich G, Llovet JM. Risk factors for HCC in HCV-cirrhosi: what we know and what we miss. J Hepatol 2006:44:1013-1016.

  2. Llovet JM. Expanding HCC criteria for liver transplant: The urgent need for prospective, robust data. Liver Transpl. 2006;12: 1741-3.


  1. Llovet JM. Hepatocellular carcinoma: Patients with increasing AFP, but no mass on ultrasound. Clinical Gastroenterology and Hepatology, 2006; 4: 29-35.

  2. Lopez P, Villanueva A, Llovet JM. Up-dated systematic review of randomized controlled trials in hepatocellular carcinoma. 2002-2005. Alim Pharmacol Ther 2006;23: 1535-47.

  3. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects on diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006, 25; 3848-56.

  4. Llovet JM., Schwartz M, Fuster J, Bruix J. Expanding criteria for HCC through downstaging prior liver transplantation: not yet there. Sem Liv Dis 2006, 26:248-53.

  5. Lopez P, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal.Liver Transpl. 2006;12: 1747-54.

  6. Lemmer E, Friedman S, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling.  Sem Liv Dis 2006;26: 373-384.